Intravenous fluids in sepsis - not exactly a rare treatment in a niche condition. Rapidly catch-up on this weeks journal club at the link for the take-home points.
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
Intravenous fluids in sepsis - not exactly a rare treatment in a niche condition. Rapidly catch-up on this weeks journal club at the link for the take-home points.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) August 11, 2022
At journal club this week, a question that impacts all intensivists - when patients with septic shock need ongoing resuscitation after their initial 30cc/kg treatment, what strategy for intravenous fluid volume should we use?
Find out in thread👇 pic.twitter.com/z0pMmEp732